Stocks · Health care · Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc.

LCTX Clue Score43
United States Fiscal year ends December CIK 0000876343 Results filed 6 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Gary S. Hogge
29 Dec 2021
SVP,Clinical & Medical Affairs
Sold after exercise
28,445
$2.44
$69.41K
Gary S. Hogge
29 Dec 2021
SVP,Clinical & Medical Affairs
Sold after exercise
9,250
$2.49
$23.03K
Gary S. Hogge
28 Dec 2021
SVP,Clinical & Medical Affairs
Sold after exercise
501,588
$2.45
$1.23M
Angus C. Russell
29 Jun 2021
Director
Sold after exercise
4,720
$2.97
$14.02K
Deborah J Andrews
29 Jun 2021
Director
Sold after exercise
19,142
$2.93
$56.09K
Brian M Culley
28 Jun 2021
President and CEO
Sold after exercise
450,000
$2.87
$1.29M
Alexandra Hernandez
30 Mar 2021
Sr Director Finance/Controller
Sold after exercise
6,000
$2.23
$13.38K

What was left out

Form 4 filings counted 203
Amendments (4/A) skipped 1
Filings about a different issuer 3
Unreadable filings 0
Joint filings 10
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 7
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 6,870,572
Sales filed before the plan box existed 1
History held since 28 Nov 2006